Understanding Managerial Accounting Concepts

By Staff Reporters

SPONSOR: http://www.MarcinkoAssociates.com

***

***

Product Costing and Valuation

Product costing deals with determining the total costs involved in the production of a good or service. Costs may be broken down into subcategories, such as variable, fixed, direct, or indirect costs. Cost accounting is used to measure and identify those costs, in addition to assigning overhead to each type of product created by the company.

Managerial accountants calculate and allocate overhead charges to assess the full expense related to the production of a good. The overhead expenses may be allocated based on the number of goods produced or other activity drivers related to production, such as the square footage of the facility. In conjunction with overhead costs, managerial accountants use direct costs to properly value the cost of goods sold and inventory that may be in different stages of production.

Marginal costing (sometimes called cost-volume-profit analysis) is the impact on the cost of a product by adding one additional unit into production. It is useful for short-term economic decisions. The contribution margin of a specific product is its impact on the overall profit of the company. Margin analysis flows into break-even analysis, which involves calculating the contribution margin on the sales mix to determine the unit volume at which the business’s gross sales equals total expenses. Break-even point analysis is useful for determining price points for products and services.

Cash Flow Analysis

Managerial accountants perform cash flow analysis in order to determine the cash impact of business decisions. Most companies record their financial information on the accrual basis of accounting. Although accrual accounting provides a more accurate picture of a company’s true financial position, it also makes it harder to see the true cash impact of a single financial transaction. A managerial accountant may implement working capital management strategies in order to optimize cash flow and ensure the company has enough liquid assets to cover short-term obligations.

When a managerial accountant performs cash flow analysis, he will consider the cash inflow or outflow generated as a result of a specific business decision. For example, if a department manager is considering purchasing a company vehicle, he may have the option to either buy the vehicle outright or get a loan. A managerial accountant may run different scenarios by the department manager depicting the cash outlay required to purchase outright upfront versus the cash outlay over time with a loan at various interest rates.

Inventory Turnover Analysis

Inventory turnover is a calculation of how many times a company has sold and replaced inventory in a given time period. Calculating inventory turnover can help businesses make better decisions on pricing, manufacturing, marketing, and purchasing new inventory. A managerial accountant may identify the carrying cost of inventory, which is the amount of expense a company incurs to store unsold items.

If the company is carrying an excessive amount of inventory, there could be efficiency improvements made to reduce storage costs and free up cash flow for other business purposes.

Constraint Analysis

Managerial accounting also involves reviewing the constraints within a production line or sales process. Managerial accountants help determine where bottlenecks occur and calculate the impact of these constraints on revenue, profit, and cash flow. Managers then can use this information to implement changes and improve efficiencies in the production or sales process.

Financial Leverage Metrics

Financial leverage refers to a company’s use of borrowed capital in order to acquire assets and increase its return on investments. Through balance sheet analysis, managerial accountants can provide management with the tools they need to study the company’s debt and equity mix in order to put leverage to its most optimal use.

Performance measures such as return on equity, debt to equity, and return on invested capital help management identify key information about borrowed capital, prior to relaying these statistics to outside sources. It is important for management to review ratios and statistics regularly to be able to appropriately answer questions from its board of directors, investors, and creditors.

Accounts Receivable (AR) Management

Appropriately managing accounts receivable (AR) can have positive effects on a company’s bottom line. An accounts receivable aging report categorizes AR invoices by the length of time they have been outstanding. For example, an AR aging report may list all outstanding receivables less than 30 days, 30 to 60 days, 60 to 90 days, and 90+ days.

Through a review of outstanding receivables, managerial accountants can indicate to appropriate department managers if certain customers are becoming credit risks. If a customer routinely pays late, management may reconsider doing any future business on credit with that customer.

Budgeting, Trend Analysis, and Forecasting

Budgets are extensively used as a quantitative expression of the company’s plan of operation. Managerial accountants utilize performance reports to note deviations of actual results from budgets. The positive or negative deviations from a budget also referred to as budget-to-actual variances, are analyzed in order to make appropriate changes going forward.

Managerial accountants analyze and relay information related to capital expenditure decisions. This includes the use of standard capital budgeting metrics, such as net present value and internal rate of return, to assist decision-makers on whether to embark on capital-intensive projects or purchases. Managerial accounting involves examining proposals, deciding if the products or services are needed, and finding the appropriate way to finance the purchase. It also outlines payback periods so management is able to anticipate future economic benefits.

Managerial accounting also involves reviewing the trendline for certain expenses and investigating unusual variances or deviations. It is important to review this information regularly because expenses that vary considerably from what is typically expected are commonly questioned during external financial audits. This field of accounting also utilizes previous period information to calculate and project future financial information. This may include the use of historical pricing, sales volumes, geographical locations, customer tendencies, or financial information.

COMMENTS APPRECIATED

Refer and Subscribe

***

***

METAVERSE: Potential in the Healthcare Industry

By Staff Reporters

***


***

The metaverse could be a huge technological change for health care, just like telemedicine and mobile device integration were in the past.

This technology has huge potential because it uses both virtual reality (VR) and augmented reality (AR) technology to work in virtual spaces: All signs point to the metaverse being widely used as a disruptive change in healthcare, from better surgical precision to therapeutic uses to social-distance accommodations and more.

But along with these improvements come new problems that will change what we know about modern healthcare. The metaverse is a paradigm shift in healthcare that everyone involved needs to be aware of. This is because it changes how medical infrastructure is built, how startup costs are covered, and how data security and privacy are handled.

To help you understand how the metaverse development services will change healthcare as a whole, let’s take a look at the pros and cons of this technology that are already making a difference in healthcare.

READ HERE: https://factstea.com/potential-metaverse-healthcare-industry/


***

DHITS: https://www.amazon.com/Dictionary-Health-Information-Technology-Security/dp/0826149952/ref=sr_1_5?ie=UTF8&s=books&qid=1254413315&sr=1-5

COMMENTS APPRECIATED

Thank You
***

Chance of leading Pharma companies producing a successful app has decreased from 2.0% (2014) to 0.5% (2016)

Pharma Report Findings

By David Ireland Berlin

[Research2Guidance ]

Leading Pharma companies continue to struggle to gain significant reach (downloads) within their target groups. While companies have cumulatively over doubled their number of active apps available on Apple App and Google Play stores (2014 – Q1 2017), most have added to the growing tail of under performers.

Why is it that Pharma companies continue to struggle in mhealth?

Have they showed other signs of improvement within their app portfolios, or through 3rd party digital eco-systems?

Only 0.5% of all apps published by the leading 12 Pharma companies have managed to achieve annual downloads of over 100K; one of the major findings from the recently published, 2nd edition Pharma App Benchmarking 2017 report by Research2Guidance.

The report builds on figures identified from the previous edition, released in 2014. It also explores the leading 3rd party digital innovation strategies, their components, and their successfulness in terms of benefits (ROI, reach etc.). While companies have on average increased their app portfolio sizes from 65 to 153, average per app annual downloads remain low at just 3.3K.

Here are three of the main reasons why:

1. Companies are competing against a growing number of mhealth competitors. According to the 2016 mhealth Developer Economics Report, there were 290K mhealth apps listed on major app stores, an increase of +174K since 2014. Annual mhealth app download growth rates are also decreasing, adding to the growing pressure.

2. Pharma app portfolios have a narrower target audience than their mhealth competitors. App portfolios of Pharma companies differ from the average mhealth app portfolio in the greater degree to which they supply apps for HCP use cases. When comparing the app categorization differences between Pharma and mhealth, Pharma tends to target a greater share of patients over healthy individuals. This in turn decreases their potential target audience, making it harder to generate downloads.

3. Apps, on average, still fall behind their mhealth competitors in terms of product quality. Pharma app portfolios are not achieving the reach and retention experienced by the average mhealth provider. Inconsistencies of design elements and cross-referencing between apps are still far too common, and continue to let Pharma app quality down.

With the hype of, for example, Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), connected devices and sensors mounting throughout the digital health industry, consumers are simply demanding more usability from their mhealth products and services.

Life-Cycles

Traditional Pharma product production life-cycles are simply incompatible when dealing with their digital offerings, given the rate of technological change. However, there are a few instances whereby Pharma companies have achieved some success with their internal app publishing.

Johnson&Johnson for example have published three of the five most downloaded Pharma apps for 2016; J&J Official 7 Minute Workout and onetouch Reveal. All three achieved over 200K downloads for 2016. The success of their leading apps has improved their portfolios overall performance in comparison to 2014.

***
***
 

All leading Pharma companies have grown their internal app portfolio size since 2014, and all but two (Abbott and Sanofi) have increased their reach.

However, thanks to the growing app portfolio size of Bayer and Novartis, and the high downloads of J&J, half of the leading Pharma companies have portfolios that fall below the average-lines. Previously, this was the case for five companies.

Taking J&J as an example, the success of a mere two or three apps can result in Pharma app market leadership.

Take Sanofi as another example. With the hype of Sanofi’s previous most downloaded app coming to an end (GoMeals), their internal app portfolio has experienced a significant decrease in annual downloads in comparison to 2014. Their portfolio has now fallen to 4th place in terms of reach behind J&J, Bayer and GSK. Novartis, Sanofi and Bayer have made the most significant strides in their app publishing activities, but are not seeing the ROI in the way of market penetration.

The newly released Pharma report goes into more company level detail on supply and demand from a platform, category, use-case and user-retention perspective. The report also analyses the 3rd party digital eco-system activities and strategies of these companies. Some appear to be relying more heavily on their 3rd party channels to source digital innovation than others, and their achievements to date give insight into which channels create the most potential for overall benefit to the Pharma company. These benefits can range from, for example, brand image improvement, digital innovation adoption, and new product distribution channels.

Assessment

Find out more about the app portfolios and digital strategies of leading Pharma companies by downloading your copy of the report today. Click here to find out more about what’s inside.                                                                                                          

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

***